By detailed molecular characterization of the underlying drug resistance mechanisms of gemcitabine treatment and the pathway-specific addition of complementing cisplatin, but also molecular inhibitors, our experiments provide evidence that RNR-modulating therapies might represent a new therapeutic option for ACC. The gene discussed is NR2E3; the disease is adrenal cortex carcinoma.